Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus, Chronic Kidney Disease
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Glargine insulin, Chronic Kidney Disease, CGMS
Eligibility Criteria
Inclusion Criteria:
- Patients with type 2 diabetes mellitus and chronic kidney disease secondary to diabetic nephropathy in stages 3 and 4 (moderate and severe nephropathy, corresponding to glomerular filtration rate of 15-59 ml/min/1.73m²) will be included in the study.
Exclusion Criteria:
- Patients with systemic neoplasias,
- HIV, chronic kidney disease or nephropathy from other etiologies,
- severe psychiatric disorders
- pregnant women.
Sites / Locations
- University of Sao Paulo
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Glargine insulin
NPH insulin
This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH.